• David Valcárcel, Jorge Sierra, Tao Wang, Fangyu Kan, Vikas Gupta, Gregory A Hale, David I Marks, Philip L McCarthy, Machteld Oudshoorn, Effie W Petersdorf, Olle Ringdén, Michelle Setterholm, Stephen R Spellman, Edmund K Waller, James L Gajewski, Susana R Marino, David Senitzer, and Stephanie J Lee.
• Hematology and Stem Cell Transplantation Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. dvalcarcel@santpau.cat
• Biol. Blood Marrow Transplant. 2011 May 1; 17 (5): 640-8.

AbstractApproximately 13% of patients lacking an HLA-identical sibling have a one-antigen-mismatched related donor (MMRD). Historically, outcomes from the use of a one-antigen MMRD were considered equivalent to those from the use of a matched unrelated donor (UD). Recent improvements in UD stem cell transplantation (SCT) resulting from better molecular HLA matching justifies investigating whether UD should be preferred over MMRD in adult patients with acute leukemia. Here, we compared the outcomes of MMRD (n = 89) and HLA-A, -B, -C, and -DRB1 allele-matched UD (n = 700) SCT reported to the Center for International Blood and Marrow Transplant Research between 1995 and 2005. The patients underwent transplantation for acute myelogenous leukemia or acute lymphoblastic leukemia in first or second complete remission. Donor type was not associated with hematologic recovery. Univariate and multivariate comparisons of MMRD versus HLA-matched UD transplants showed no statistically significant differences in overall survival, disease-free survival, treatment-related mortality, relapse, or 100-day grade III-IV acute graft-versus-host disease (GVHD). MMRD SCT was associated with a lower rate of chronic GVHD at 1 year (35% vs 47%; P = .03), which was confirmed by multivariate analysis (relative risk, 0.58; 95% confidence interval, 0.39-0.85; P < .01). According to our data, HLA-matched UD and MMRD SCT are associated with comparable survival. Given that less chronic GVHD was observed in the MMRD transplantations, this option, when available, remains the first choice in patients with acute leukemia without an HLA-identical sibling in need of allogeneic SCT.Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

29 keywords...

hide…